(EMAILWIRE.COM, July 08, 2008 ) Denver, CO - LegalView.com, the number one legal resource on the Web, offered information through its mesothelioma information (http://mesothelioma.legalview.com/blog ) blog on an opportunity for pleural mesothelioma cancer victims to participate in a clinical trial being conducted at the Mesothelioma Center at New York-Presbyterian Hospital and Columbia University Medical Center. The clinical trial hopes to improve surgical and radiation treatments for patients of pleural mesothelioma cancer. Currently, the most common treatment for patients of the asbestos-induced cancer is removal of the victim's lung. Individuals who suffer from pleural mesothelioma or any other form of mesothelioma cancer are advised to speak with an experienced mesothelioma lawyer (http://mesothelioma.legalview.com/find-mesothelioma-lawer.aspx), as there may be potential for monetary compensation from a mesothelioma lawsuit (http://mesothelioma.legalview.com).
Mesothelioma cancer is caused by the inhalation of asbestos fibers, which are derived from mining vermiculite. During the 20th century, the United States was a hotspot for vermiculite mines, which inadvertently may have exposed thousands of miners as well as their families and friends to asbestos fibers and dust. Asbestos was seen as a cheaply made and excellent fire retardant form of insulation; it was quickly implemented into an array of buildings across the country including elementary schools, universities, apartments, homes, office buildings and hospitals. Individuals who may be at risk for exposure to asbestos should locate a mesothelioma law firm who will be able to provide resources for a potential mesothelioma lawsuit including offering a mesothelioma attorney (http://mesothelioma.legalview.com)and legal consultation.
In addition to the extensive mesothelioma information portal available through LegalView, there is a library of legal issues with information available at www.LegalView.com/. For example, LegalView offers information on a range of pharmaceutical controversies including information on the Chantix side effects and the Levaquin risks as well as a newly revamped Avandia portal.
Chantix, a smoking cessation drug, has been associated with side effects ranging from depression and erratic behavior to suicidal thoughts and actions among patients taking the drug. The Chantix risks(http://chantix.legalview.com) were first discovered in late 2007 and have allegedly been linked to nearly 40 suicides of individuals consuming the prescription drug.
Another controversial prescription drug is Levaquin, which is an antibiotic used to treat a range of bacterial infections among patients. Although it was recently approved for the use of individuals under the age of 18 it has been associated with causing tendon rupture among patients regardless of short- or long-term use. An array of studies have found the Levaquin tendon rupture (http://levaquin.legalview.com) and it has been associated with patients who took the drug more than two years earlier.
LegalView also offered a newly re-launched Avandia information portal. Avandia is a type 2 diabetes drug that has been discovered to potentially cause an increased risk of heart failure as well as early on-set osteoporosis. For additional information on the Avandia risks(http://avandia.legalview.com), visit http://avandia.legalview.com/.
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including: